Sign in

CIK 0001689375

  • Accelerated filer
  • Smaller reporting company
  • Emerging growth company

Entrada Therapeutics, Inc.

Sign in to watch
Ticker
TRDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813983399
Phone
+1 857-305-1825
Business address
ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
Former names
CycloPorters, Inc.
  1. 4 Planned sale Chief Operating Officer sold 7,097 shares at an average $18.03 ($127,938)
  2. 4 Planned sale Chief Scientific Officer sold 17,878 shares at an average $18.03 ($322,389)
  3. 4 Exercise or conversion Chief Financial Officer acquired 8,790 shares (option exercise)
  4. 4 Planned sale Chief Financial Officer sold 17,500 shares at an average $15.01 ($262,648)
  5. 4 Planned sale Chief Operating Officer sold 15,982 shares at an average $15.42 ($246,403)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Planned sale President and CEO sold 2,000 shares at $13.71 ($27,422)
  11. 4 Planned sale President and CEO sold 2,092 shares at $18.01 ($37,675)
  12. 4 Planned sale Chief Scientific Officer sold 3,961 shares at $18.00 ($71,316)
  13. 4/A Grant or award President and CEO acquired 49,650 shares (grant or award)
  14. 4/A Grant or award Chief Scientific Officer acquired 14,200 shares (grant or award)
  15. 4/A Grant or award Chief Financial Officer acquired 14,200 shares (grant or award)
  16. 4/A Grant or award Chief Medical Officer acquired 14,200 shares (grant or award)
  17. 4/A Grant or award Chief Operating Officer acquired 14,200 shares (grant or award)
  18. 4 Derivatives Options or other derivatives
  19. 3 Insider Initial Statement of Ownership
  20. 4 Planned sale President and CEO sold 2,000 shares at an average $14.72 ($29,435)

Page 7 of 13 · 242 filings